cmbio

Executive Summary

Cmbio is a Denmark-based biotechnology company founded in 2019 that specializes in multi-omics and microbiome science. Operating as a research and innovation partner, Cmbio provides end-to-end services, advanced bioinformatics, and a cloud-based platform for analyzing complex data from metagenomics, metabolomics, transcriptomics, and other omics layers. The company's mission is to generate actionable insights to improve human, animal, and planetary health. With over 50 employees and a private status, Cmbio has established itself as a key player in the drug discovery and AI/machine learning categories, serving clients globally from its Copenhagen headquarters. Cmbio's platform differentiates itself by integrating multiple omics data streams, enabling comprehensive biological insights that are critical for precision medicine and microbiome-based therapeutics. The company's service-oriented business model reduces barriers for pharmaceutical and academic partners to access cutting-edge multi-omics analysis. While Cmbio has not publicly disclosed funding rounds or valuation, its growing employee count and partnerships suggest steady expansion. Given the increasing interest in the microbiome and multi-omics fields, Cmbio is well-positioned to capitalize on the growing demand for integrated bioinformatics solutions. However, as a private entity with limited public disclosures, its near-term prospects rely on new partnerships, platform upgrades, or expansion into new therapeutic areas.

Upcoming Catalysts (preview)

• Q3 2026Announcement of Major Pharmaceutical Partnership65% success
• Q4 2026Launch of New AI-Powered Multi-Omics Platform Module70% success
• H1 2027Expansion into Animal or Planetary Health Market via Strategic Collaboration50% success